Trial record 1 of 4 for:    "galactosemia"
Previous Study | Return to List | Next Study

Inactive FSH in Galactosemia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2010 by Maastricht University Medical Center.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Galactosemie Vereniging Nederland (The Dutch Galactosemia Society)
Information provided by:
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT00619333
First received: February 6, 2008
Last updated: January 11, 2010
Last verified: January 2010
  Purpose

The aim of the study is to investigate whether inactive FSH plays a role in the development of Premature Ovarian Failure in women with Classic Galactosemia


Condition Intervention
Galactosemia
Premature Ovarian Failure
Drug: follitropin and lutropin

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: The Role of Inactive Follicle Stimulating Hormone in Ovarian Dysfunction in Galactosemia

Resource links provided by NLM:


Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • Estradiol response [ Time Frame: 3 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 25
Study Start Date: March 2007
Estimated Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1 Drug: follitropin and lutropin
follitropin and lutropin

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of galactosemia through GALT-activity analysis and/or mutation analysis
  • Premature Ovarian Failure with FSH > 30 U/l

Exclusion Criteria:

  • Gynecological cancers and/or unexplained vaginal bleeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00619333

Locations
Netherlands
Maastricht University Hospital
Maastricht, Netherlands
Sponsors and Collaborators
Maastricht University Medical Center
Galactosemie Vereniging Nederland (The Dutch Galactosemia Society)
Investigators
Principal Investigator: Estela Rubio-Gozalbo, MD, PhD Maastricht University Hospital
  More Information

No publications provided

Responsible Party: Dr. M. E. Rubio-Gozalbo, Academic Hospital Maastricht
ClinicalTrials.gov Identifier: NCT00619333     History of Changes
Other Study ID Numbers: MEC 06-2-073
Study First Received: February 6, 2008
Last Updated: January 11, 2010
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Additional relevant MeSH terms:
Galactosemias
Menopause, Premature
Primary Ovarian Insufficiency
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Carbohydrate Metabolism, Inborn Errors
Metabolic Diseases
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases
Follicle Stimulating Hormone
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 27, 2014